alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM IDS MANAGED
FUTURES II, L.P. FOR THE SECOND QUARTER OF 1999 AND IS QUALIFIED IN ITS ENTIRETY
BY REFERENCE TO SUCH 10-Q.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               SEP-30-1999
<CASH>                                       9,935,502
<SECURITIES>                                         0
<RECEIVABLES>                                   32,541
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             9,968,043
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                               9,968,043
<CURRENT-LIABILITIES>                          186,577
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                   9,781,466
<TOTAL-LIABILITY-AND-EQUITY>                 9,968,043
<SALES>                                              0
<TOTAL-REVENUES>                           (1,061,874)
<CGS>                                                0
<TOTAL-COSTS>                                  223,698
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                            (1,285,572)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (1,285,572)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (1,285,572)
<EPS-BASIC>                                    (79.49)
<EPS-DILUTED>                                  (79.49)


</TABLE>
<PAGE>

                                  [LETTERHEAD]




                 Consent of George A. Hieronymus and Company, L.L.C.
                                           

We consent to the incorporation by reference in this Amended Annual Report on 
Form 10-K/A, filed with the Securities and Exchange Commission by NHP 
Incorporated (NHP) of our reports dated as shown in Exhibit A with respect to 
the audit of those entities as shown in Exhibit A for the year ended December 
31, 1994, and the incorporation by reference of such report into NHP's 
Registration Statement on Form S-8 (No. 333-11933), NHP's Registration 
Statement on Form S-8 (No. 333-11863), NHP's Registration Statement of Form 
S-8 (333-11917), NHP's Registration Statement on Form S-8 (333-11857), and 
NHP's Registration Statement on Form S-8 (333-08137).




/s/ George A. Hieronymus and Company L.L.C.
--------------------------------------------
George A. Hieronymus and Company, L.L.C.
Mobile, Alabama
October 3, 1997





<PAGE>

                                E X H I B I T   A



<TABLE>
<CAPTION>
<S>                                                       <C>
Real Estate Partnership                                   Report Date
-----------------------                                   -----------

Athens Arms Associates                                    January 27, 1995

Colonial Terrace I Associates                             January 27, 1995

Colonial Terrace II Associates                            January 27, 1995


</TABLE>
Exhibit 99.1

     Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002


In connection with the filing of the Healthcare  Properties,  L.P. Form 10-Q for
the quarterly period ended September 30, 2002, the undersigned  hereby certifies
that:

1.   The Report fully complies with the  requirement of Section 13 (a) or 15 (d)
     of the Securities Exchange Act of 1934, as amended, and

2.   The information  contained in the Report fairly  presents,  in all material
     respects, the financial condition and results of operations of Registrant.


                                         /s/ Robert Lankford
                                         -----------------------------------
                                         Robert Lankford
                                         Chief executive officer and
                                         Chief financial officer of the
                                         General Partner
**Exhibit 32**

 

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350AS ADOPTEDPURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2003.**

 

The certifications set forth below are herebysubmitted to the Securities and Exchange Commission pursuant to, and solely forthe purpose of complying with, Section 1350 of Chapter 63 of Title 18 ofthe United States Code in connection with the filing on the date hereof withthe Securities and Exchange Commission of the Quarterly Report on Form 10-Qof the Company for the quarter ended March 31, 2005.

 

Each of the undersigned hereby certifies in his capacity as an officerof Citizens Bancshares Corporation and subsidiaries (the “Company”) that, tohis knowledge on the date of this certification, the Quarterly Report of theCompany on Form 10-Q for the period ended March 31, 2005 fullycomplies with the requirements of Section 13(a) of the SecuritiesExchange Act of 1934 and that the information contained in such report fairlypresents, in all material respects, the financial condition of the Company atthe end of such period and the results of operations of the Company for suchperiod.

 

 
| Date:  | May 13, 2005 | By:                                   | /s/ James E. Young   |   |
|--------|-------------------|---------------------------------------|----------------------|--------|
|   |              | James E. Young                        |
|   |              | President and Chief Executive Officer |
|   |              |                                  |                 |
| Date:  | May 13, 2005 | By:                                   | /s/ Willard C. Lewis |   |
|   |              | Willard C. Lewis                      |
|   |              | Senior Executive Vice President and   |
|   |              | Chief Operating Officer               |
|   |              |                                  |                 |
| Date:  | May 13, 2005 | By:                                   | /s/ Samuel J. Cox    |   |
|   |              | Samuel J. Cox                         |
|   |              | Senior Vice President and             |
|   |              | Chief Financial Officer               |

 

----
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1240 Carbon dioxide. ( a ) Carbon dioxide (empirical formula CO2, CAS Reg. No. 124-38-9) occurs as a colorless, odorless, noncombustible gas at normal temperatures and pressures. The solid form, dry ice, sublimes under atmospheric pressure at a temperature of −78.5 °C. Carbon dioxide is prepared as a byproduct of the manufacture of lime during the “burning” of limestone, from the combustion of carbonaceous material, from fermentation processes, and from gases found in certain natural springs and wells.
( b ) The ingredient must be of a purity suitable for its intended use.
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitations other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a leavening agent as defined in § 170.3(o)(17) of this chapter; a processing aid as defined in § 170.3(o)(24) of this chapter; and a propellant, aerating agent, and gas as defined in § 170.3(o)(25) of this chapter.
( 2 ) The ingredient is used in food at levels not to exceed current good manufacturing practice.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[48 FR 57270, Dec. 29, 1983, as amended at 73 FR 8607, Feb. 14, 2008]
H. R. 7507 

One Hundred Eighteenth Congress 

of the 

United States of America 

AT THE SECOND SESSION 

Begun and held at the City of Washington on Wednesday, 

the third day of January, two thousand and twenty-four 

An Act 

To designate the facility of the United States Postal Service located at 203 East 

6th Street in Lexington, Nebraska, as the ‘William E. and Elsie L. Barrett 

Post Office Building. 

Be it enacted by the Senate and House of Representatives of 

the United States of America in Congress assembled, 

SECTION 1. WILLIAM E. AND ELSIE L. BARRETT POST OFFICE 

BUILDING. 

(a) DESIGNATION.—The facility of the United States Postal 

Service located at 203 East 6th Street in Lexington, Nebraska, 

shall be known and designated as the ‘‘William E. and Elsie L. 

Barrett Post Office Building’’. 

(b) REFERENCES.—Any reference in a law, map, regulation, 

document, paper, or other record of the United States to the facility 

referred to in subsection (a) shall be deemed to be a reference 

to the ‘‘William E. and Elsie L. Barrett Post Office Building’’. 

Speaker of the House of Representatives. 

Vice President of the United States and

President of the Senate.
* Pursuant to Local Rule 47.5, the court has determined that

this opinion should not be published and is not precedent except under the limited circumstances set forth in Local Rule 47.5.4.

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 96-20656

BOB STRAUS, Plaintiff-Appellee,

versus

RON ANGLE, Defendant-Appellant.

Appeal from the United States District Court For the Southern District of Texas

April 22, 1997

Before REYNALDO G. GARZA, HIGGINBOTHAM, and JONES, Circuit Judges.

PER CURIAM: *

We are persuaded that the district court lacked personal
jurisdiction. The judgment below is reversed. The case is

remanded with instructions to the district court to dismiss for

want of jurisdiction.
# C_2014102EN.01001901.xml

| 7.4.2014 | EN | Official Journal of the European Union | C 102/19 |
| --- | --- | --- | --- |

7.4.2014

EN

Official Journal of the European Union

C 102/19

---

Request for a preliminary ruling from the Bundesgerichtshof (Germany) lodged on 27 January 2014 — Bodenverwertungs- und -verwaltungs GmbH (BVVG) and Others

(Case C-39/14)

2014/C 102/26

Language of the case: German

Referring court

Referring court

Bundesgerichtshof

Parties to the main proceedings

Parties to the main proceedings

Applicant: Bodenverwertungs- und -verwaltungs GmbH (BVVG)

Applicant:

Other parties: Thomas Erbs, Ursula Erbs

Other parties:

Consent authority: Landkreis Jerichower Land

Consent authority:

Question referred

Question referred

Does Article 107(1) TFEU preclude a national provision such as Paragraph 9(1), no. 3, GrdstVG, which, for the improvement of the social structure of agriculture, in effect prohibits an agency such as Bodenverwertungs- und -verwaltungs GmbH (BVVG), which must be ascribed to the State, from selling to the highest bidder in a public call for tenders agricultural land available for sale, if the highest bid is grossly disproportionate to the value of the land?

---
§ 582.5434 Magnesium phosphate. ( a ) *Product.* Magnesium phosphate (di- and tribasic).
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
§ 524.1044c Gentamicin ophthalmic ointment. ( a ) *Specifications.* Each gram of ointment contains gentamicin sulfate equivalent to 3 milligrams of gentamicin.
( b ) *Sponsors.* See Nos. 000061 and 017033 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs and cats* — ( 1 ) *Amount.* Apply approximately a 1/2-inch strip to the affected eye 2 to 4 times a day.
( 2 ) *Indications for use.* For treatment of conjunctivitis caused by susceptible bacteria.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[69 FR 47363, Aug. 5, 2004, as amended at 77 FR 64717, Oct. 23, 2012; 85 FR 4208, Jan. 24, 2020; 88 FR 16549, Mar. 20, 2023]
<PAGE>   1
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549


                                 ---------------


                                    FORM 8-K

                                 CURRENT REPORT


                     Pursuant to Section 13 or 15(d) of the

                         Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) JANUARY 29, 1999


                              CELLPRO, INCORPORATED
--------------------------------------------------------------------------------
               (Exact name of registrant as specified in charter)



        DELAWARE                         0-19472               94-3087971
--------------------------------------------------------------------------------
(State or other jurisdiction           (Commission            (IRS Employer
of incorporation)                      File Number)         Identification No.)



  22215 26TH AVENUE S.E., BOTHELL, WA                             98021
--------------------------------------------------------------------------------
(Address of principal executive offices)                        (Zip Code)



Registrant's telephone number, including area code (206) 485-7644


                                       N/A
--------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)

<PAGE>   2
Item 5.  Other Events

              A.     Closing of the Asset Purchase Agreement with Nexell
                     Therapeutics Inc., a subsidiary of VIMRx Pharmaceuticals,
                     Inc. ("VIMRX"), whereby CellPro, Incorporated ("CellPro")
                     sold essentially all of its research, intellectual
                     property, patents, antibodies and related cell banks, and
                     licensed rights, in exchange for $3 million in VIMRX
                     securities. In this transaction, 1,882,215 registered
                     shares of VIMRX common stock with certain restrictions on
                     sale were issued to CellPro. The total number of shares is
                     based on a pricing formula that was the average closing
                     price for the 15 business days which ended three days prior
                     to the closing, or $1.59 per share.
<PAGE>   3
                                   SIGNATURES

               Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.


                                       CellPro, Incorporated
                                            (Registrant)


Date:  February 4, 1999                /s/ Mark J. Handfelt
                                       -----------------------------------------
                                       Name:  Mark J. Handfelt
                                       Title: Executive Vice President and 
                                              General Counsel
# L_2019145EN.01008502.xml

| 4.6.2019 | EN | Official Journal of the European Union | L 145/85 |
| --- | --- | --- | --- |

4.6.2019

EN

Official Journal of the European Union

L 145/85

---

Corrigendum to Commission Implementing Decision (EU) 2019/570 of 8 April 2019 laying down rules for the implementation of Decision No 1313/2013/EU of the European Parliament and of the Council as regards rescEU capacities and amending Commission Implementing Decision 2014/762/EU (notified under document C(2019) 2644)

(
  Official Journal of the European Union L 99 of 10 April 2019
  )

On page 1, first line of point 2 of the Annex:

for:

‘Contribute to the extinction of large forest and vegetal by performing aerial firefighting’

read:

‘Contribute to the extinction of large forest and vegetal fires by performing aerial firefighting’.

---
Editorial Note on Part 570
Editorial Note: Nomenclature changes to part appear at 88 FR 45066, July 14, 2023.

§ 570.18 Tolerances for related food additives. ( a ) Food additives that cause similar or related pharmacological effects will be regarded as a class, and in the absence of evidence to the contrary, as having additive toxic effects and will be considered as related food additives.
( b ) Tolerances established for such related food additives may limit the amount of a common component that may be present, or may limit the amount of biological activity (such as cholinesterase inhibition) that may be present or may limit the total amount of related food additives that may be present.
( c ) Where food additives from two or more chemicals in the same class are present in or on a food, the tolerance for the total of such additives shall be the same as that for the additive having the lowest numerical tolerance in this class, unless there are available methods that permit quantitative determination of the amount of each food additive present or unless it is shown that a higher tolerance is reasonably required for the combined additives to accomplish the physical or technical effect for which such combined additives are intended and that the higher tolerance will be safe.
( d ) Where residues from two or more additives in the same class are present in or on a food and there are available methods that permit quantitative determination of each residue, the quantity of combined residues that are within the tolerance may be determined as follows: ( 1 ) Determine the quantity of each residue present.
( 2 ) Divide the quantity of each residue by the tolerance that would apply if it occurred alone, and multiply by 100 to determine the percentage of the permitted amount of residue present.
( 3 ) Add the percentages so obtained for all residues present.
( 4 ) The sum of the percentages shall not exceed 100 percent.
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.85 Caramel. ( a ) *Identity.* ( 1 ) The color additive caramel is the dark-brown liquid or solid material resulting from the carefully controlled heat treatment of the following food-grade carbohydrates: Dextrose. Invert sugar. Lactose. Malt sirup. Molasses. Starch hydrolysates and fractions thereof. Sucrose.
( 2 ) The food-grade acids, alkalis, and salts listed in this subparagraph may be employed to assist caramelization, in amounts consistent with good manufacturing practice. ( i ) Acids: Acetic acid. Citric acid. Phosphoric acid. Sulfuric acid. Sulfurous acid.
( ii ) Alkalis: Ammonium hydroxide. Calcium hydroxide U.S.P. Potassium hydroxide. Sodium hydroxide.
( iii ) Salts: Ammonium, sodium, or potassium carbonate, bicarbonate, phosphate (including dibasic phosphate and monobasic phosphate), sulfate, and sulfite.
( 3 ) Polyglycerol esters of fatty acids, identified in § 172.854 of this chapter, may be used as antifoaming agents in amounts not greater than that required to produce the intended effect.
( 4 ) Color additive mixtures for food use made with caramel may contain only diluents that are suitable and that are listed in this subpart as safe in color additive mixtures for coloring foods.
( b ) *Specifications.* Caramel shall conform to the following specifications: Lead (as Pb), not more than 10 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 0.1 part per million.
( c ) *Uses and restrictions.* Caramel may be safely used for coloring foods generally, in amounts consistent with good manufacturing practice, except that it may not be used to color foods for which standards of identity have been promulgated under section 401 of the act unless added color is authorized by such standards.
( d ) *Labeling.* The label of the color additive and any mixtures prepared therefrom and intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( e ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health and therefore batches thereof are exempt from the certification requirements of section 721(c) of the act.
<TABLE> <S> <C>


<ARTICLE>  5
<LEGEND>
This schedule contains summary financial information extracted from unaudited
financial statements for the three month period ending March 31, 1997 and is
qualified in its entirety by reference to such financial statements
</LEGEND>
<CIK>          0000813812
<NAME>         Riverside Park Associates Limited Partnership
<MULTIPLIER>   1
<CURRENCY>     U.S. Dollars
       
<S>                                           <C>
<PERIOD-TYPE>                                 3-MOS
<FISCAL-YEAR-END>                                    DEC-31-1997
<PERIOD-START>                                       JAN-01-1997
<PERIOD-END>                                         MAR-31-1997
<EXCHANGE-RATE>                                                1
<CASH>                                                 2,207,162
<SECURITIES>                                                   0
<RECEIVABLES>                                                  0
<ALLOWANCES>                                                   0
<INVENTORY>                                                    0
<CURRENT-ASSETS>                                               0
<PP&E>                                                72,591,006
<DEPRECIATION>                                      (29,646,497)
<TOTAL-ASSETS>                                        46,922,043
<CURRENT-LIABILITIES>                                          0
<BONDS>                                                        0
<COMMON>                                                       0
<PREFERRED-MANDATORY>                                          0
<PREFERRED>                                                    0
<OTHER-SE>                                             (482,961)
<TOTAL-LIABILITY-AND-EQUITY>                          46,922,043
<SALES>                                                        0
<TOTAL-REVENUES>                                       2,657,485
<CGS>                                                          0
<TOTAL-COSTS>                                                  0
<OTHER-EXPENSES>                                         987,304 
<LOSS-PROVISION>                                               0
<INTEREST-EXPENSE>                                       959,581
<INCOME-PRETAX>                                        (101,696) 
<INCOME-TAX>                                                   0
<INCOME-CONTINUING>                                    (101,696) 
<DISCONTINUED>                                                 0
<EXTRAORDINARY>                                                0
<CHANGES>                                                      0
<NET-INCOME>                                           (101,696) 
<EPS-PRIMARY>                                           (174.28) 
<EPS-DILUTED>                                           (174.28)
        


</TABLE>